Last reviewed · How we verify
Gadoteridol (ProHance)
Gadoteridol is a gadolinium-based contrast agent that enhances magnetic resonance imaging (MRI) by shortening the T1 relaxation time of water protons in tissues.
Gadoteridol is a gadolinium-based contrast agent that enhances magnetic resonance imaging (MRI) by shortening the T1 relaxation time of water protons in tissues. Used for MRI contrast enhancement for central nervous system imaging, MRI contrast enhancement for body imaging including liver, kidney, and other organs.
At a glance
| Generic name | Gadoteridol (ProHance) |
|---|---|
| Sponsor | Bayer |
| Drug class | Gadolinium-based contrast agent |
| Target | Water protons (T1 relaxation enhancement) |
| Modality | Small molecule |
| Therapeutic area | Diagnostic Imaging |
| Phase | Phase 3 |
Mechanism of action
Gadoteridol is a macrocyclic gadolinium chelate complex that distributes into the extracellular space and increases the relaxivity of nearby water molecules, resulting in enhanced signal intensity on T1-weighted MRI images. This allows for improved visualization and characterization of tissues and lesions during MRI examinations. The macrocyclic structure provides high thermodynamic and kinetic stability, reducing the risk of gadolinium release.
Approved indications
- MRI contrast enhancement for central nervous system imaging
- MRI contrast enhancement for body imaging including liver, kidney, and other organs
Common side effects
- Headache
- Nausea
- Dizziness
- Injection site reactions
- Gadolinium retention (rare with macrocyclic agents)
Key clinical trials
- Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI) (EARLY_PHASE1)
- Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years (PHASE4)
- A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems) (PHASE3)
- Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis (PHASE2)
- Intraventricular Stasis In Cardiovascular Disease
- A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems (PHASE3)
- Quantitative MRI for Functional Assessment Following SBRT for Spinal Metastases (NA)
- Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gadoteridol (ProHance) CI brief — competitive landscape report
- Gadoteridol (ProHance) updates RSS · CI watch RSS
- Bayer portfolio CI